Glaukos Plunges 11.07% Despite Sales Surge

Glaukos's stock price plummeted by 11.07% in pre-market trading on May 1, 2025, marking a significant decline for the company.

Glaukos reported a quarterly loss of $0.22 per share for the first quarter of 2025, which was better than the estimated loss of $0.33 per share. The company's operating loss for the first quarter of 2025 was $20.7 million, a notable improvement from the $39.1 million operating loss in the same period last year.

Despite the loss, Glaukos saw a 25% increase in net sales for the quarter, reaffirming its full-year guidance. The company's revenue for the first quarter reached $106.7 million, surpassing market projections of $102.8 million. This growth was attributed to the successful execution of key strategic plans and the advancement of its pipeline of novel, dropless platform technologies.

Glaukos's chairman and chief executive officer, Thomas Burns, highlighted the company's strong start to the year and sustained growth acceleration. He emphasized the company's commitment to advancing the standard of care and improving outcomes for patients suffering from chronic eye diseases.